GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harrow Inc (NAS:HROW) » Definitions » Earnings per Share (Diluted)

Harrow (Harrow) Earnings per Share (Diluted) : $-0.76 (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Harrow Earnings per Share (Diluted)?

Harrow's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.27. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.76.

Harrow's EPS (Basic) for the three months ended in Dec. 2023 was $-0.27. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.76.

Harrow's EPS without NRI for the three months ended in Dec. 2023 was $-0.27. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.49.

During the past 3 years, the average EPS without NRIGrowth Rate was -47.70% per year.

During the past 13 years, Harrow's highest 3-Year average EPS without NRI Growth Rate was 58.00% per year. The lowest was -343.80% per year. And the median was 19.30% per year.


Harrow Earnings per Share (Diluted) Historical Data

The historical data trend for Harrow's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harrow Earnings per Share (Diluted) Chart

Harrow Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -0.13 -0.69 -0.51 -0.75

Harrow Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 -0.22 -0.14 -0.13 -0.27

Competitive Comparison of Harrow's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harrow's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harrow's PE Ratio distribution charts can be found below:

* The bar in red indicates where Harrow's PE Ratio falls into.



Harrow Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Harrow's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-24.411-0)/32.617
=-0.75

Harrow's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-9.148-0)/35.397
=-0.26

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Harrow  (NAS:HROW) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Harrow Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Harrow's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Harrow (Harrow) Business Description

Industry
Traded in Other Exchanges
N/A
Address
102 Woodmont Boulevard, Suite 610, Nashville, TN, USA, 37205
Harrow Inc is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year.
Executives
Mark L Baum director, 10 percent owner, officer: Chief Executive Officer C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Martin A. Makary director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Van Horn R. Lawrence director 354 COOL SPRINGS BLVD., SUITE 106, FRANKLIN TN 37067
Andrew Boll officer: VP, Accounting and Reporting 437 S HWY 101, STE 209, SOLANA BEACH CA 92075
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Perry J. Sternberg director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Teresa Sparks director 40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Robert J Kammer director, 10 percent owner, officer: Chairman of the Board 1440 28TH STREET, SUITE 9, BOULDER CO 80303
Longboard Capital Advisors, Llc other: Institutional Investor 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad other: Managing Mbr of Longboard Cap. 1312 CEDAR ST., SANTA MONICA CA 90405
Clayton D Edwards officer: Chief Operating Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Anthony Principi director 2300 WEST PLANO PARKWAY, M/S D2420, PLANO TX 75244
Donald Paul Miloni 10 percent owner 1425 GREENWOOD LANE, GREENWOOD VILLAGE CO 80125
John P. Saharek officer: Chief Commercial Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130